Why carry out this study?

The relative efficacy of the treatment of AS may differ between males and females, hence a better understanding of the sex-attributable differences in response to biologic therapy is important.

This is the first post hoc analysis from a large, pooled dataset of patients with AS, reporting the efficacy and safety of an IL-17 inhibitor by sex.

What was learned from the study?

High retention rates for both males and females were observed in this pooled dataset in contrast to previous studies with TNF inhibitors.

Secukinumab demonstrated comparable improvements in the assessed outcome measures across males and females through Week 52, except for ASDAS-CRP ID response rates.